Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BYArchives of endocrinology and metabolism

Changes of serum fibroblast growth factor 23 (FGF23) and Klotho in diabetic kidney disease and their correlation with coronary artery calcification: a retrospective study.

  • Yan Hong1,2
  • Jiahui Wang1,2
  • Qiandi Lu1,2
  • Wenjuan Sun1,2
  • Jinzhu Sun1,2
  1. 1Department of Nephrology, Jiangnan University Medical Center, Wuxi, Jiangsu, China.
  2. 2Department of Nephrology, Wuxi No. 2 People's Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi, Jiangsu, China.
Read full textPDFDOICite

Abstract

Objective

This study investigated the association among fibroblast growth factor 23 (FGF23), Klotho, and coronary artery calcification (CAC) in patients with diabetic kidney disease (DKD).Subjects and methods

A total of 176 DKD patients and 160 age-and diabetes-matched controls were retrospectively analyzed. We measured serum FGF23 and Klotho levels by enzyme-linked immunosorbent assay and assessed CAC by CAC scoring. Correlation and receiver operating characteristic analyses were performed to evaluate the associations of these biomarkers with CAC and their ability to discriminate CAC.Results

FGF23 levels were significantly higher and Klotho levels were lower in patients with DKD than in controls. FGF23 correlated negatively with estimated glomerular filtration rate and positively with the albumin-to-creatinine ratio and blood urea nitrogen, whereas Klotho correlated positively with estimated glomerular filtration rate and negatively with albumin-to-creatinine ratio and blood urea nitrogen. In patients with CAC, FGF23 levels were higher and Klotho levels were lower. Receiver operating characteristic analysis showed that both FGF23 and Klotho discriminated CAC, and FGF23 showed a higher area under curve than Klotho. Correlation analysis further confirmed the association of FGF23 and Klotho with CAC severity.Conclusion

FGF23 and Klotho were associated with renal impairment and CAC in patients with DKD and may serve as potential biomarkers of renal and cardiovascular risk.

Related

  1. Fibroblast Growth Factor 23 and Osteoprotegerin in Vascular Calcification among Patients without Advanced Chronic Kidney Disease
    Keisuke Senda, Nami Teraoka, Kazuma Masuda +6
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  2. Serum T50 is not independently associated with coronary artery calcification in early chronic kidney disease
    Clinical kidney journalPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Segment-Level Evaluability of Dedicated Non-ECG-Gated Coronary CT Angiography: Associations with Calcification, Heart Rate, Vessel Territory, and Caliber
    Kun Wang, Aiyun Sun, Xia Qiu +3
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Balancing innovation and safety in percutaneous treatment of coronary artery calcification: the evolving role of cutting balloon technology
    Pierre Chenard, Claudiu Ungureanu, Giuseppe Colletti +5
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Cardiovascular medicineCrossref
  5. Balancing innovation and safety in percutaneous treatment of coronary artery calcification
    Ayman Helal, Andrew Ladwiniec, Abdul Mozid +10
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@article{hong2026changes,
  title = {{Changes of serum fibroblast growth factor 23 (FGF23) and Klotho in diabetic kidney disease and their correlation with coronary artery calcification: a retrospective study.}},
  author = {Yan Hong and Jiahui Wang and Qiandi Lu and Wenjuan Sun and Jinzhu Sun},
  journal = {Archives of endocrinology and metabolism},
  year = {2026},
  month = oct,
  doi = {10.20945/2359-4292-2026-0125},
  url = {https://europepmc.org/article/MED/42905600},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Changes of serum fibroblast growth factor 23 (FGF23) and Klotho in diabetic kidney disease and their correlation with coronary artery calcification: a retrospective study.
AU  - Yan Hong
AU  - Jiahui Wang
AU  - Qiandi Lu
AU  - Wenjuan Sun
AU  - Jinzhu Sun
PY  - 2026
DA  - 2026/10/20
JO  - Archives of endocrinology and metabolism
DO  - 10.20945/2359-4292-2026-0125
UR  - https://europepmc.org/article/MED/42905600
AB  - Objective  This study investigated the association among fibroblast growth factor 23 (FGF23), Klotho, and coronary artery calcification (CAC) in patients with diabetic kidney disease (DKD).Subjects and methods  A total of 176 DKD patients and 160 age-and diabetes-matched controls were retrospectively analyzed. We measured serum FGF23 and Klotho levels by enzyme-linked immunosorbent assay and assessed CAC by CAC scoring. Correlation and receiver operating characteristic analyses were performed to evaluate the associations of these biomarkers with CAC and their ability to discriminate CAC.Results  FGF23 levels were significantly higher and Klotho levels were lower in patients with DKD than in controls. FGF23 correlated negatively with estimated glomerular filtration rate and positively with the albumin-to-creatinine ratio and blood urea nitrogen, whereas Klotho correlated positively with estimated glomerular filtration rate and negatively with albumin-to-creatinine ratio and blood urea nitrogen. In patients with CAC, FGF23 levels were higher and Klotho levels were lower. Receiver operating characteristic analysis showed that both FGF23 and Klotho discriminated CAC, and FGF23 showed a higher area under curve than Klotho. Correlation analysis further confirmed the association of FGF23 and Klotho with CAC severity.Conclusion  FGF23 and Klotho were associated with renal impairment and CAC in patients with DKD and may serve as potential biomarkers of renal and cardiovascular risk.
SN  - 2359-3997
SN  - 2359-4292
ER  -